Since p-stage I lung adenocarcinoma incidence is significantly increased in patients with EGFR mutation, it is critical to select an appropriate surgical procedure, especially that with significant effects on the incision margin and recurrence. This evidence concerns the gene EGFR and lung adenocarcinoma.